10X Capital Venture Acquisition Corp. III does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or assets. It intends to identify business opportunities in the field of consumer internet, e-commerce, software, healthcare, transportation/mobility, financial services, artificial intelligence, automation, data science, and Software-as-a-Service. The company was incorporated in 2021 and is based in New York, New York.
IPO Year: 2022
Exchange: NYSE
| Date | Price Target | Rating | Analyst |
|---|
SC 13G/A - 10X Capital Venture Acquisition Corp. III (0001848948) (Subject)
SC 13G/A - 10X Capital Venture Acquisition Corp. III (0001848948) (Subject)
SC 13G/A - 10X Capital Venture Acquisition Corp. III (0001848948) (Subject)
SC 13G - 10X Capital Venture Acquisition Corp. III (0001848948) (Subject)
SC 13G/A - 10X Capital Venture Acquisition Corp. III (0001848948) (Subject)
SC 13G/A - 10X Capital Venture Acquisition Corp. III (0001848948) (Subject)
SC 13G - 10X Capital Venture Acquisition Corp. III (0001848948) (Subject)
SC 13G - 10X Capital Venture Acquisition Corp. III (0001848948) (Subject)
SC 13G - 10X Capital Venture Acquisition Corp. III (0001848948) (Subject)
25-NSE - 10X Capital Venture Acquisition Corp. III (0001848948) (Subject)
8-K - 10X Capital Venture Acquisition Corp. III (0001848948) (Filer)
8-K - 10X Capital Venture Acquisition Corp. III (0001848948) (Filer)
25-NSE - 10X Capital Venture Acquisition Corp. III (0001848948) (Subject)
DEF 14A - 10X Capital Venture Acquisition Corp. III (0001848948) (Filer)
8-K - 10X Capital Venture Acquisition Corp. III (0001848948) (Filer)
8-K - 10X Capital Venture Acquisition Corp. III (0001848948) (Filer)
PRE 14A - 10X Capital Venture Acquisition Corp. III (0001848948) (Filer)
NT 10-Q - 10X Capital Venture Acquisition Corp. III (0001848948) (Filer)
425 - 10X Capital Venture Acquisition Corp. III (0001848948) (Subject)
3 - 10X Capital Venture Acquisition Corp. III (0001848948) (Issuer)
3 - 10X Capital Venture Acquisition Corp. III (0001848948) (Issuer)
4 - 10X Capital Venture Acquisition Corp. III (0001848948) (Issuer)
3/A - 10X Capital Venture Acquisition Corp. III (0001848948) (Issuer)
New York, NY, April 23, 2024 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE:VCXB) ("10X III"), announced today that New York Stock Exchange Regulation, Inc., by letter dated April 17, 2024 (the "Notice"), notified 10X III that it was not in compliance with the NYSE American LLC's ("NYSE American") continued listing standards because 10X III did not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the "Annual Report"), which was due on April 16, 2024. 10X III was unable to timely file the Annual Report because 10X III's independent registered public accounting firm required additional time to complete its review of 10X III's finan
New York, NY, Jan. 31, 2024 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE:VCXB, VCXB.U, VCXB WS))) ("10X III"), announced today that NYSE Regulation ("NYSER"), by letter dated January 29, 2024 (the "Notice"), notified 10X III that it is not currently in compliance with Section 1003(b)(i) of the NYSE American LLC Company Guide because 10X III has fewer than 300 public shareholders. The Notice provides that 10X III has until February 28, 2024 (the "Compliance Plan Due Date") to submit a plan to NYSER outlining how it intends to cure the deficiency and regain compliance with the NYSE American LLC's (the "NYSE American") continued listing standards by January 14, 2025. T
NEW YORK, NY (United States), Jan. 08, 2024 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III ("10X III") (NYSE:VCXB), a publicly traded special purpose acquisition company, announced today that, subject to approval by the board of directors, it expects David Weisburd, the current Chief Operating Officer and Head of Origination, to succeed Hans Thomas as Chief Executive Officer of 10X III, and expects Osman Ahmed to succeed Oliver Wriedt as President. Mr. Thomas will remain as Chairman of the board of directors. About 10X Capital 10X Capital is an alternative asset management firm leveraging advancements in data analytics & AI to generate signals, deliver insights, and drive
New York, NY, Nov. 28, 2023 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE:VCXB) ("10X III"), announced today that New York Stock Exchange Regulation, Inc., by letter dated November 21, 2023 (the "Notice"), notified 10X III that it was not in compliance with the NYSE American LLC's ("NYSE American") continued listing standards because 10X III did not timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the "Quarterly Report"), which was due on November 20, 2023. As reported in the Form 12b-25 filed by 10X III with the Securities and Exchange Commission ("SEC") on November 14, 2023, 10X III's independent registered public accou
New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE:VCXB, VCXB, VCXB WS))) ("10X III") today announced that it is transferring the listing of its Class A ordinary shares, par value $0.0001 per share ("Class A Ordinary Shares"), redeemable warrants, each exercisable to purchase one Class A Ordinary Share at a price of $11.50 per share (the "Warrants"), and units, each consisting of one Class A Ordinary Share and one-half of one Warrant (the "Units" and, together with the Class A Ordinary Shares and the Warrants, the "Listed Securities"), from the New York Stock Exchange (the "NYSE") to the NYSE American LLC (the "NYSE American"). 10X III's decisio
Addimmune's investigational cell therapy, AGT103-T, makes gene modifications to the patients' immune cells (T cells) that harden those cells against HIV infection and depletion, thus allowing those cells to target and kill HIV instead of being "killed" by the virus. Thirty-eight million people are living with HIV globally, with 1.2 million in the U.S and 2.3 million in Europe. Although HIV has suitable treatments, those treatments are expensive, lifelong, and can often have side effects.Addimmune successfully completed the Phase I trial for AGT103-T by showing positive safety results in seven patients. The Phase I trial, along with another sponsor-initiated follow-on study, showed active i
Sparks Energy, Inc. ("Sparks"), a power infrastructure services firm and a leader in power restoration management, has entered into a merger agreement with 10X Capital Venture Acquisition Corp. III (NYSE:VCXB) ("10X III"); the newly combined company will be listed on the New York Stock Exchange under the ticker symbol "SPKS".Sparks provides critical electric transmission and distribution infrastructure recovery and repair services for utility customers across the United States, serving as the first responder for regional, state, and local power outages caused by environmental events such as snow, ice, wind, fire, flood and hurricanes.The rise in the frequency and severity of climate change-d
Russell Read will join the 10X team at the Milken Institute 2022 Middle East & Africa Summit in Abu Dhabi Nov 17-18 NEW YORK, Nov. 16, 2022 (GLOBE NEWSWIRE) -- 10X Capital, the New York based alternative investment firm, today announced that Dr. Russell Read, former Chief Investment Officer ("CIO") of CalPERS, the Alaska Permanent Fund, and the Gulf Investment Corporation, and former deputy CIO of Deutsche Bank's Deutsche Asset Management, is joining 10X Capital as its Chief Investment Officer. Dr. Read will report to 10X Capital's founder and CEO, Hans Thomas, and will oversee the Firm's investment strategies globally, across both private funds and publicly listed vehicles.